Indeed, our data and data from other investigators suggest that the survival benefit from IL-6 plus ICI blockade is modest, but when combined with additional agents, such as CD40 stimulation or radiotherapy, this therapeutic strategy can durably prolong survival in glioblastoma preclinical models15. Here, CD40 is linked to glioblastoma.